StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Analysts at StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Tuesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

NASDAQ ADXS opened at $0.03 on Tuesday. The firm’s fifty day moving average price is $0.03 and its 200 day moving average price is $0.04. Ayala Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $0.78. The company has a market capitalization of $1.28 million, a price-to-earnings ratio of 0.00 and a beta of 1.68.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.